Baxalta Pharmaceutical Company is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.

Baxalta Pharmaceutical Company

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Metric
Company Name	Baxalta Pharmaceutical Company	ADMA Biologics, Inc.
Symbol		ADMA
MSH ID	COM:BAXALTAPHARMACEUTICAL	COM:ADMABIOLOGICS
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	US
Stage
Employee Count		624
Website	baxaltapharmaceutical.com	admabiologics.com
LinkedIn
Founders

Metric
Market Cap		2.78B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		258.21M
Revenue (LTM)
Revenue (NTM)
Gross Profit		88.22M
EBITDA		29.96M
Operating Income		21.63M
Net Income		-28.24M
EPS		-0.13
Diluted EPS		-0.13
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.39
Operating Profit Margin		0.16
EBITDA Margin		0.12
Net Profit Margin		-0.01
Return on Equity		-0.02
Return on Assets		-0.01
Return on Capital Employed		0.15

COM:BAXALTAPHARMACEUTICAL

Baxalta Pharmaceutical Company

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-27.46
P/B Ratio		7.71
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		6.20
EV Multiple		52.25

Metric
Days Sales Outstanding		48.79
Days Payables Outstanding		24.41
Days Inventory Outstanding		377.54
Operating Cycle		441.50
Cash Conversion Cycle		405.00
Asset Turnover		0.81

Metric
Operating Cash Flow		8.80M
Free Cash Flow		3.82M
Cash Flow to Debt		0.15
Operating Cash Flow/Sales		0.08
Free Cash Flow Yield		-0.02

Metric
Cash & Equivalents		51.35M
Accounts Receivable		-11.92M
Inventory		172.91M
Goodwill		3.53M
Debt to Capitalization		0.49
Debt to Assets		0.44
Current Ratio		6.54
Quick Ratio		1.79

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.02
R&D to Revenue		0.02
SG&A to Revenue